Canadian Journal of Gastroenterology and Hepatology

Clinical Study

Effect of Admission Time on the Outcomes of Liver Cirrhosis with Acute Upper Gastrointestinal Bleeding: Regular Hours versus Off-Hours Admission

Table 4

Characteristics of patients with liver cirrhosis and AUGIB after propensity matching in validation cohort.


Variables		Propensity matching patients		P value
Variables	Overall (n=40)	Regular hours (n=20)	Off-hours (n=20)	P value

Age (years)	56.86 (20.57-75.64)	60.64 (20.57-75.64)	55.52 (35.18-74.33)	0.160
Sex (male)	28 (70%)	13 (65%)	15 (75%)	0.490
Etiology of Liver Diseases				0.622
HBV	9 (22.5%)	4 (20%)	5 (25%)
HCV	4 (10%)	2 (10%)	2 (10%)
Alcohol Abuse	14 (35%)	7 (35%)	7 (35%)
Drug Related	2 (5%)	0 (0%)	2 (10%)
Autoimmune Liver Diseases	1 (2.5%)	1 (5%)	0 (0%)
Other or Unclear Etiology	10 (25%)	6 (30%)	4 (20%)
Laboratory Tests
Red Blood Cell (10¹²/L)	2.625 (1.65-3.89)	2.58 (1.69-3.89)	2.705 (1.65-3.78)	0.968
Hemoglobin (g/L)	74.50 (38.00-126.00)	77.00 (53.00-122.00)	72.50 (38.00-126.00)	0.473
White Blood Cell (10⁹/L)	4.40 (1.80-14.90)	4.40 (2.20-11.70)	4.35 (1.80-14.90)	0.839
Platelet Count (10⁹/L)	72.50 (27.00-301.00)	72.50 (27.00-301.00)	72.00 (32.00-145.00)	0.978
Total Bilirubin (umol/L)	18.10 (5.50-106.10)	16.85 (5.50-50.90)	18.10 (8.50-106.10)	0.256
Direct Bilirubin (umol/L)	7.85 (2.20-60.10)	7.10 (2.20-41.50)	7.95 (3.00-60.10)	0.675
Indirect Bilirubin (umol/L)	9.50 (2.80-46.00)	8.55 (2.80-22.10)	10.00 (5.40-46.00)	0.148
Albumin (g/L)	30.65 (18.00-39.20)	30.85 (19.00-38.60)	30.00 (18.00-39.20)	1
Alanine Aminotransferase (U/L)	21.805 (6.79-88.77)	21.805 (9.44-72.47)	20.415 (6.79-88.77)	0.756
Aspartate Aminotransferase (U/L)	25.635 (10.74-136.00)	28.38 (11.00-88.79)	25.635 (10.74-136.00)	0.978
Alkaline Phosphatase (U/L)	80.10 (40.34-234.00)	80.94 (40.34-234.00)	78.245 (46.24-149.45)	0.705
Gamma-glutamyl Transpeptidase (U/L)	41.245 (7.69-295.00)	40.48 (13.71-254.00)	42.765 (7.69-295.00)	0.935
Blood Urea Nitrogen (mmol/L)	7.395 (2.98-18.83)	7.055 (2.98-18.83)	8.40 (4.65-18.72)	0.245
Serum Creatinine (umol/L)	70.11 (34.90-143.10)	66.68 (42.60-95.20)	74.255 (34.90-143.10)	0.117
Potassium (mmol/L)	3.95 (3.10-4.66)	3.88 (3.10-4.66)	3.98 (3.27-4.59)	0.330
Sodium (mmol/L)	139.10 (124.00-145.70)	138.50 (135.00-141.40)	139.45 (124.00-145.70)	0.279
PT (seconds)	15.80 (13.30-24.50)	15.40 (13.30-23.90)	16.05 (13.50-24.50)	0.417
APTT (seconds)	36.25 (30.80-47.50)	35.90 (30.80-45.20)	37.15 (32.20-47.50)	0.351
INR	1.275 (1.02-2.19)	1.255 (1.08-2.08)	1.31 (1.02-2.19)	0.516
Child-Pugh Score	8.00 (5.00-12.00)	8.00 (5.00-12.00)	7.00 (5.00-12.00)	0.836
Child-Pugh A/B/C	14 (35%)/22 (55%)/4 (10%)	7 (35%)/12 (60%)/1 (5%)	7 (35%)/10 (50%)/3 (15%)	0.544
MELD Score	5.82 (-2.38-23.19)	5.51 (-1.04-14.75)	6.51 (-2.38-23.19)	0.245
Recalibrated MELD Score	-4.11 (-5.80- -0.51)	-4.17 (-5.53- -2.26)	-3.96 (-5.80- -0.51)	0.245
ALBI Score	-1.67 (-2.62- -0.49)	-1.73 (-2.44- -0.49)	-1.67 (-2.62- -0.60)	0.787
Esophageal Varices (No/Mild/Moderate/Severe)	2 (5%)/5 (12.5%)/6 (15%)/27 (67.5%)	1 (5%)/3 (15%)/3 (15%)/13 (65%)	1 (5%)/2 (10%)/3 (15%)/14 (70%)	0.971
Treatment
Endoscopic Treatment	38 (95%)	19 (95%)	19 (95%)	1
Sengstaken Blakemore	0 (0%)	0(0%)	0(0%)	NA
Somatostatin	39 (97.5%)	20 (100%)	19 (95%)	0.311
Blood Transfusion	21 (52.5%)	9 (45%)	12 (60%)	0.342
PPIs	40 (100%)	20 (100%)	20 (100%)	NA
Surgery	0 (0%)	0 (0%)	0 (0%)	NA
5-day Re-bleeding After Treatment	5 (12.5%)	2 (10%)	3 (15%)	0.633
Death During Hospitalization	1 (2.5%)	0 (0%)	1 (5%)	0.311
Length of Stay (days)	11.95 (5.73-31.06)	11.95 (5.73-21.95)	11.28 (7.52-31.06)	0.441
Total Payment (¥)	24,961.33 (11,212.15-81,125.52)	25,985.45 (15,513.68-56,952.12)	24,961.33 (11,212.15-81,125.52)	0.829

Data are expressed as median (range) or frequency (percentage).
Abbreviations. AUGIB: acute upper gastrointestinal bleeding; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PT: Prothrombin time; APTT: activated partial thromboplastin time; INR, International normalized ratio; MELD: model for end-stage liver disease; ALBI: albumin-bilirubin; PPIs: proton pump inhibitors; ¥: Renminbi.